Q3 2025 Earnings Call Transcript November 7, 2025 Fulgent Genetics, Inc. beats earnings expectations. Reported EPS is ...

Objective: To describe the joint manifestations associated with clonal haematopoiesis and to compare patients with and ...

Myriad Genetics (MYGN) stock is downgraded from a "Buy" to "Hold" due to flat Q3 2025 earnings and limited near-term revenue ...

The consensus estimate for Q3 2025 revenue is $204.90 million, and the earnings are expected to come in at -$0.22 per share.

Genetic testing company Myriad Genetics (NASDAQ:MYGN) in Q3 CY2025, but sales fell by 3.6% year on year to $205.7 million.

Prenatal testing revenue in the third quarter of 2025 grew 2% year-over-year, reflecting ongoing expansion of payer coverage, particularly for Foresight Expanded Carrier Screen. Prenatal volume over ...

Q: I have a Cavalier King Charles Spaniel who is 9. Recently, over the last two weeks, he developed an involuntary, what I would call, muscle spasm. I can see ...

As of late October 2025, the U.S. stock market is experiencing mixed results, with Federal Reserve Chair Jerome Powell indicating uncertainty about a potential rate cut in December. In such a climate, ...

The Canadian — who holds the Guinness record for world’s tallest teen — stepped onto the court for the first time with 2:09 ...

Nov 7 - James D. Watson, the brilliant but controversial American biologist whose 1953 discovery of the structure of DNA, the molecule of heredity, ushered in the age of genetics and provided the ...